Priyadarshini Pathak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Priyadarshini Pathak has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aileen O'SHea
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
5 shared publications - Akwi W. Asombang
Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
5 shared publications - Andrea Hansen
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
5 shared publications - Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
5 shared publications - Beatrice Awasthi
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
5 shared publications - Bidish Patel
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
5 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
DEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of differential expressed genes
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessDEG table1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of differential expressed genes
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of concordant differential expressed genes between cell lines and patient tumors
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data2 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
List of concordant differential expressed genes between cell lines and patient tumors
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Table outlines patient representation in general and on study
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 - Representation1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Table outlines patient representation in general and on study
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Elraglusib dosing of PDAC lines. Principle component analysis of spatial gene expression focused on Epithelial and Immune compartments. Stromal compartment spatial gene analysis. UMAPs of snRNA seq analysis.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Elraglusib dosing of PDAC lines. Principle component analysis of spatial gene expression focused on Epithelial and Immune compartments. Stromal compartment spatial gene analysis. UMAPs of snRNA seq analysis.
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 869-882
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Purpose: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasi-mesenchymal (QM) transcriptional states, with differences in sensitivity to FOLFIRINOX (FFX). Glycogen synthase kinase 3β (GSK-3β) is a key regulator of PDAC cell epithelial-to-mesenchymal transition (EMT). Patients and Methods: In vitro analysis of PDAC cell lines combined with multiomic analysis of data from a GSK-3β inhibitor trial (NCT05077800) was conducted to evaluate treatment effects on EMT. Results: GSK-3β inhibition with elraglusib (ELRA) drives QM PDAC cells toward an E state, demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEG) in PDAC cell lines with tumors from patients with PDAC treated in a safety cohort combining FFX, ELRA, and losartan demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. The synergy of ELRA with cytotoxic doses of FFX in 3D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit, with three of six patients experiencing a partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating a baseline high proportion of QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor-associated macrophages, CD4/CD8 lymphocytes, and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq, and ferumoxytol-enhanced MRI. Conclusions: GSK-3β blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor-suppressive immune microenvironment.
- 9 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 869-882
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Purpose: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasi-mesenchymal (QM) transcriptional states, with differences in sensitivity to FOLFIRINOX (FFX). Glycogen synthase kinase 3β (GSK-3β) is a key regulator of PDAC cell epithelial-to-mesenchymal transition (EMT). Patients and Methods: In vitro analysis of PDAC cell lines combined with multiomic analysis of data from a GSK-3β inhibitor trial (NCT05077800) was conducted to evaluate treatment effects on EMT. Results: GSK-3β inhibition with elraglusib (ELRA) drives QM PDAC cells toward an E state, demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEG) in PDAC cell lines with tumors from patients with PDAC treated in a safety cohort combining FFX, ELRA, and losartan demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. The synergy of ELRA with cytotoxic doses of FFX in 3D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit, with three of six patients experiencing a partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating a baseline high proportion of QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor-associated macrophages, CD4/CD8 lymphocytes, and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq, and ferumoxytol-enhanced MRI. Conclusions: GSK-3β blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor-suppressive immune microenvironment.